[Chromosomal Abnormalities Associated with Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma]

To investigate the prognostic value of karyotypic abnormalities in evaluation of prognosis of patients with multiple myeloma.

The clinical and laboratory data of patients with newly diagnosed multiple myeloma (NDMM) were retrospectively analyzed in our hospital from May 2010 to May 2016. Patients who carried t(4; 14), t(14; 16) or 17P^- (at least one of them) were defined as the patients with high-risk karyotype, whereas patients characterized by the absence of the above-mentioned abnormalities were defined as patients with standard-risk karyotype. PFS (progression-free survival, PFS) and OS (over all survival, OS) time was compared between the 2 groups.

There were 110 cases in the high-risk group, and 302 cases in the standard-risk group. The clinical characteristics, such as age, sex, ISS stage and treatment regimen etc were not statistically different between 2 groups. The median OS time of patients in the high-risk and standard-risk groups were 42 months (CI 95%: 34.375-49.625 months) and 53 months (CI 95%: 46.310-59.690 months) (P<0.05). The median PFS time of patients in the high-risk group and standard-risk groups was 21 months (CI95%: 17.198-24.802 months) and 27 months (CI95%: 23.406-30.594 months) (P<0.05).

Among patients with newly diagnosed MM, the PFS and OS time in the patients with high-risk karyotype is shorter than that in patients with standard-risk karyotyp.